This trial has been completed.

Condition psoriasis
Treatment etanercept
Sponsor Universitaire Ziekenhuizen Leuven
Collaborator Pfizer
Start date January 2015
End date September 2016
Trial size 56 participants
Trial identifier NCT02322580, S56818


The purpose of this study is to investigate the association between trough serum levels of etanercept, antibodies towards etanercept and its effectiveness in psoriasis patients.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
etanercept Enbrel®

Primary Outcomes

trough serum etanercept concentration
time frame: one year
anti-etanercept serum concentration
time frame: one year

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Age from 18 years on, male or female - Established diagnosis of psoriasis - Etanercept either on monotherapy or in combination with acitretin (Neotigason®), given according to the current EU SmPC including the safety measures. - Patients who give informed consent for this study

Additional Information

Official title Intermittent Versus Continuous Treatment: an Observational Monocentric Study Investigating the Association Between Trough Levels of Enbrel and Therapy Regimen
Trial information was received from ClinicalTrials.gov and was last updated in December 2016.
Information provided to ClinicalTrials.gov by Universitaire Ziekenhuizen Leuven.